Novel use of ec-sod and method for preparing thereof

Abstract

The present invention relates to compositions for preventing or treating angiogenesis-mediated diseases or allergic diseases which contain, as an active ingredient, an EC-SOD protein or a vector having a polynucleotide encoding thereof. The EC-SOD protein or the vector having a polynucleotide encoding the EC-SOD protein has the effect on inhibiting angiogenesis by inhibiting the expression of VEGF and MMP-9 which induce angiogenesis. Therefore, the EC-SOD protein or the vector may be useful for preventing or treating angiogenesis-mediated diseases. And the EC-SOD protein or the vector having a polynucleotide encoding said EC-SOD protein also has the effect on inhibiting over-differentiation of Th2 cells which cause allergic diseases, inhibiting transcription factor (NF-κ B), and reducing degranulation of human mast cells. Accordingly, the EC-SOD protein or the vector may be useful for preventing or treating allergy diseases. In addition, the inventive method for preparing an EC-SOD protein may be used in preparing an EC-SOD protein having the activity on a large scale. Therefore, the inventive method may be useful industrially.

1 . A composition for preventing or treating angiogenesis-mediated diseases comprising an EC-SOD protein as an active ingredient. 
     
     
         2 . The composition for preventing or treating angiogenesis-mediated diseases of  claim 1 , wherein the EC-SOD protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, and 5. 
     
     
         3 . The composition for preventing or treating angiogenesis-mediated diseases of  claim 1 , wherein the diseases is selected from the group consisting of cancer, diabetes, rheumatoid arthritis, arteriosclerosis, hemangioma, angiofibroma, diabetic retinopathy, retinopathy of prematurity, neovascular glaucoma, corneal diseases caused by angiogenesis, degenerative spots, macular degeneration, pterygium, retinal degeneration, retrolental fibroplasia, Granular conjunctivitis, telangiectasia, pyogenic granuloma and acne. 
     
     
         4 . A composition for preventing or treating angiogenesis-mediated diseases comprising a vector having a polynucleotide encoding the EC-SOD protein of  claim 1  as an active ingredient. 
     
     
         5 . The composition for preventing or treating angiogenesis-mediated diseases of  claim 4 , wherein the polynucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NOs: 2, 4, and 6. 
     
     
         6 . The composition for preventing or treating angiogenesis-mediated diseases of  claim 4 , wherein the diseases is selected from the group consisting of cancer, diabetes, rheumatoid arthritis, arteriosclerosis, hemangioma, angiofibroma, diabetic retinopathy, retinopathy of prematurity, neovascular glaucoma, corneal diseases caused by angiogenesis, degenerative spots, macular degeneration, pterygium, retinal degeneration, retrolental fibroplasia, Granular conjunctivitis, telangiectasia, pyogenic granuloma and acne. 
     
     
         7 . A composition for preventing or treating allergic diseases comprising an EC-SOD protein as an active ingredient. 
     
     
         8 . The composition for preventing or treating allergic diseases of  claim 7 , wherein the EC-SOD protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, and 5. 
     
     
         9 . The composition for preventing or treating allergic diseases of  claim 7 , wherein the allergic diseases is selected from the group consisting of allergic asthma, allergic rhinitis, allergic otitis media, anaphylatic shock, allergic skin disease, atopic dermatitis, psoriasis, contact allergic dermatitis and urticaria. 
     
     
         10 . A composition for preventing or treating allergic diseases comprising a vector having a nucleotide encoding the EC-SOD protein of  claim 7  as an active ingredient. 
     
     
         11 . The composition for preventing or treating allergic diseases of  claim 10 , wherein the polynucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NOs: 2, 4, and 6. 
     
     
         12 . The composition for preventing or treating allergic diseases of  claim 10 , wherein the allergic diseases is selected from the group consisting of allergic asthma, allergic rhinitis, allergic otitis media, anaphylatic shock, allergic skin disease, atopic dermatitis, psoriasis, contact allergic dermatitis and urticaria. 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . A method for preventing or treating angiogenesis-mediated disease, comprising administering to a subject in need thereof an effective amount of an EC-SOD protein. 
     
     
         20 . Use of an EC-SOD protein for preparation a therapeutic agent for angiogenesis-mediated diseases. 
     
     
         21 . A method for preventing or treating angiogenesis-mediated disease, comprising administering to a subject in need thereof an effective amount of a vector having a polynucleotide encoding an EC-SOD protein. 
     
     
         22 . Use of a vector having a polynucleotide encoding an EC-SOD protein for preparation a therapeutic, agent for angiogenesis-mediated diseases. 
     
     
         23 . A method for preventing or treating allergic diseases comprising administering to a subject in need thereof an effective amount of an EC-SOD protein. 
     
     
         24 . Use of an EC-SOD protein for preparation a therapeutic agent for allergic diseases. 
     
     
         25 . A method for preventing or treating allergic diseases comprising administering to a subject in need thereof an effective amount of a vector having a polynucleotide encoding an EC-SOD protein 
     
     
         26 . Use of a vector having a polynucleotide encoding an EC-SOD protein for preparation a therapeutic agent for allergic diseases.